Exchange Traded Concepts LLC Decreases Stock Holdings in Bristol Myers Squibb Company $BMY

Exchange Traded Concepts LLC reduced its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 81.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 116,233 shares of the biopharmaceutical company’s stock after selling 523,740 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Bristol Myers Squibb were worth $6,270,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb in the second quarter valued at about $25,000. Harbor Capital Advisors Inc. boosted its holdings in shares of Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 313 shares during the period. KERR FINANCIAL PLANNING Corp bought a new stake in shares of Bristol Myers Squibb in the third quarter worth about $35,000. JPL Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb in the third quarter worth about $36,000. Finally, Total Investment Management Inc. purchased a new position in Bristol Myers Squibb during the 2nd quarter valued at about $38,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Positive Phase 3 data for Camzyos (mavacamten) in adolescents — SCOUT‑HCM showed efficacy and safety in teens with symptomatic obstructive hypertrophic cardiomyopathy, supporting a potential label expansion and added addressable market for an established cardiovascular product. This is a clear pipeline upside that could lift long‑term revenue expectations. Bristol Myers Presents Positive SCOUT‑HCM Results
• Positive Sentiment: Supportive real‑world/switch data for Cobenfy — Phase 4/open‑label switch results indicate symptom stability and acceptable tolerability when patients transition from other oral atypical antipsychotics to Cobenfy (xanomeline + trospium). These data help the schizophrenia franchise by reducing switching risk and may aid uptake. Open‑Label Switch Study for Cobenfy
• Neutral Sentiment: Investor write‑ups and buy theses highlight valuation and dividend appeal — recent articles argue BMY’s P/E and forward metrics, plus dividend yield and upcoming ex‑dividend timing, make the stock attractive for income/value investors, which can support a base under the share price but may not trigger rapid re‑rating. Is BMY a Good Stock to Buy?
• Neutral Sentiment: Ex‑dividend timing noted — coverage points out BMY goes ex‑dividend soon, which can attract short‑term dividend seekers but has limited fundamental impact. BMY Looks Like A Good Stock, Ex‑Dividend Soon
• Neutral Sentiment: Mixed analyst sentiment — roughly 60% of covering analysts show mixed ratings even though the consensus price target (~$63) implies modest upside; this split can cap near‑term momentum until clearer fundamentals emerge. Mixed Analyst Sentiment
• Negative Sentiment: Fundamental headwinds remain from prior earnings and guidance dynamics — recent quarterly EPS missed expectations and FY‑2026 guidance is below some street forecasts, which keeps near‑term valuation under pressure and helps explain downward stock moves despite clinical positives. (Background company filings and recent results.)

Analysts Set New Price Targets

BMY has been the subject of a number of recent analyst reports. Citigroup upped their price target on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Barclays started coverage on Bristol Myers Squibb in a research note on Thursday, February 19th. They set an “overweight” rating and a $75.00 target price on the stock. Royal Bank Of Canada began coverage on Bristol Myers Squibb in a report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 target price for the company. Leerink Partners lifted their price target on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a report on Tuesday, January 13th. Finally, Bank of America raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $52.00 to $61.00 in a research report on Monday, December 15th. Nine research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Bristol Myers Squibb has an average rating of “Hold” and an average target price of $61.41.

Bristol Myers Squibb Stock Performance

Bristol Myers Squibb stock opened at $58.59 on Monday. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The stock’s 50 day simple moving average is $58.82 and its two-hundred day simple moving average is $52.27. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The stock has a market cap of $119.62 billion, a price-to-earnings ratio of 16.98, a PEG ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). The firm had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The firm’s revenue was up 1.3% on a year-over-year basis. During the same period in the prior year, the company posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be issued a $0.63 dividend. The ex-dividend date is Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio is 73.04%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.